Financial Performance

2022 was a year in which we set all-time highs in several
financial categories - including Revenue and Adjusted Diluted EPS.

Grid of multiple images that comprise the CEO...
Financial Performance

Three-year summary for the years ended December 31

Millions, Except Per Share Data
% Change







Reported net income (1)






Reported diluted EPS (1)






Adjusted income (2)






Adjusted diluted EPS (2)






Net cash provided by operating activities






Cash dividends paid






  1. Reported net income is defined as Net income attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.
  2. Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP Net income attributable to Pfizer Inc. common shareholders and reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. The Adjusted income and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the Non-GAAP Financial Measure: Adjusted Income section of Management’s Discussion and Analysis of Financial Condition and Results of Operations(link is external) in Pfizer’s 2022 Annual Report on Form 10-K for an explanation of how management uses these non-GAAP measures, reconciliations to the most directly comparable U.S. GAAP measures and additional information.

Detailed information on our financial and operational performance can be found in our 2022 Annual Report on Form 10-K.

Top 10 Medicines and Vaccines

Take a look at our breakdown of the top medicines and vaccines by revenue from 2022.

Select an option below
  • $37,806 million
  • $18,933 million
    (nirmatrelvir tablets and ritonavir tablets)
  • $6,480 million
    ELIQUIS® (apixaban) 2
  • $6,337 million
    PREVNAR® Family 3
  • $5,120 million
    IBRANCE® (palbociclib)
  • $2,447 million
    VYNDAQEL® Family 4
  • $1,796 million
    XELJANZ® (tofacitinib)
  • $1,198 million
    XTANDI® (enzalutamide) 5
  • $1,003 million
    ENBREL® (etanercept)
  • $1,003 million
    INLYTA® (axitinib)
  1. COMIRNATY refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), the COMIRNATY Original/Omicron BA.1 Vaccine, and COMIRNATY Original/Omicron BA.4/BA.5 Vaccine. COMIRNATY includes direct sales and alliance revenues related to sales of the above-mentioned vaccines.
  2. ELIQUIS includes alliance revenues and direct sales.
  3. PREVNAR Family includes revenues from PREVNAR 13/PREVENAR 13 (pediatric and adult) and PREVNAR 20/APEXXNAR (adult).
  4. VYNDAQEL Family includes global revenues from VYNDAQEL, as well as revenues for VYNDAMAX in the U.S. and VYNMAC in Japan.
  5. XTANDI represents alliance revenues.